Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer

Meng, Xiangjiao; Huang, Zhaoqin; Wang, Renben; J, Yu

doi:10.5582/bst.8.11

Cited by 23 publications

(13 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A comprehensive summary of these findings is contained in a number of good reviews that highlight the frequently conflicting and inconclusive results obtained for most of the markers evaluated. [41][42][43][44] Hur et al recently published a study on the tissue microarray evaluation of a panel of markers that have been shown to be significantly related to response in several studies (p53, p21, B-cell CLL/lymphoma 2, BCL2-associated X protein, EGFR, cytochrome c oxidase subunit II, mutL homolog 1, mutS homolog 2, Ku70, VEGF, TS, Ki-67). A predictive model and a scoring system based on the 4 most significant biomarkers (p53, p21, VEGF, and Ki-67) was subsequently developed, and showed that sufficient predictive accuracy can only be obtained by taking into account the expression level of several biomarkers.…”

Section: Protein Expressionmentioning

confidence: 98%

Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer

Molinari

Matteucci

Caroli

et al. 2015

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Section: Protein Expressionmentioning

confidence: 98%

Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer

Molinari

Matteucci

Caroli

et al. 2015

Clinical Colorectal Cancer

View full text Add to dashboard Cite

“…Response to preoperative chemoradiation can sometimes even achieve a complete pathological remission, which is an important prognostic factor for locally advanced rectal cancer. During the last years, several studies have described markers and gene expression profiles to predict response to neoadjuvant chemoradiation [ 10 , 11 ]. Despite some encouraging results in defining markers/ gene profiles, there is still controversy between different studies.…”

Section: Introductionmentioning

confidence: 99%

Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer

et al. 2015

View full text Add to dashboard Cite

BackgroundSeveral studies have shown, that circulating tumor cells (CTC) have a negative prognostic value in colorectal cancer patients. Aim of this study was to evaluate the role of CTC in specifically rectal cancer patients regarding the influence on overall survival and to elucidate the impact of CTC in predicting response after chemoradiation (RCTX).MethodsIn this prospective monocentric study 267 patients with rectal cancer were included. Patients with locally advanced tumors were treated with RCTX followed by surgery. The primary endpoints were: Evaluation of CTC at the time of surgery and correlation with main tumor characteristics, response to neoadjuvant RCTX and overall survival (OS). CTC were detected in the blood using CK20 RT-PCR.ResultsSixty-three patients were treated with neoadjuvant RCTX. In 46.8 % of the patients receiving neoadjuvant RCTX CTC were detected, which was significantly higher than in the group without RCTX (p = 0.002). Histopathologic regression after RCTX was evident in 27.8 % of the patients. In the subgroup of responders after RCTX we found CTC at a significantly lower rate than in non-responders (p = 0.03). No significant association was found between CTC detection and tumor characteristics and OS. The OS was significantly improved for responders compared to non-responders (p = 0.007).ConclusionsResponders after neoadjuvant RCTX had a lower incidence of CTC compared to non-responders, which might be a result of effective systemic and local treatment prior to surgery. Interestingly, detection of CTC did not correlate with tumor stage and OS, which is in contrast to previous reports of patients with colon cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1989-z) contains supplementary material, which is available to authorized users.

show abstract

“…It is important to find markers that can predict responses to RCT in order to spare poor responders this treatment and to detect potential response-modifying pathways. Although several promising markers have been unveiled there is no consensus regarding such markers [ 3 - 5 ].…”

Section: Introductionmentioning

confidence: 99%

Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma

et al. 2015

View full text Add to dashboard Cite

Locally advanced rectal adenocarcinoma is treated with radiochemotherapy (RCT) before surgery. The response to RCT is heterogeneous and consensus regarding reliable predictors is lacking. Since the ERK pathway is implicated in radioprotection, we examined pretreatment biopsies from 52 patients by immunohistochemistry for phosphorylated ERK (pERK). Immunostaining for pERK was considerably enhanced by use of alkaline demasking. Nuclear staining occurred in both cancer cells and stromal cells. Blind-coded sections were scored by 2 independent investigators. In patients showing no residual tumor after RCT (TRG1), staining for pERK in cancer, but not stromal, cell nuclei was significantly weaker than in patients showing a poor RCT response (TRG1 vs TRG4: p = 0.0001). Nuclear staining for pERK predicted poor responders, as illustrated by receiver operating characteristic curves with an area under curve of 0.86 (p = 0.0007) and also predicted downstaging (area under curve: 0.76; p = 0.01). A number of controls documented the specificity of the optimized staining method and results were confirmed with another pERK antibody. Thus, staining for pERK in cancer cell nuclei can predict the response to RCT and may help spare poor responders this treatment. These results also raise the question whether inhibitors of ERK activation may serve as response modifiers of RCT.

show abstract

Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer

Cited by 23 publications

References 80 publications

Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer

Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer

Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer

Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma

Contact Info

Product

Resources

About